摘要
新辅助化疗对局部进展期胃癌的整体疗效已经得到认可。然而,由于肿瘤的异质性,新辅助化疗对一部分患者无效。肿瘤退缩分级(TRG)在评估胃癌新辅助化疗疗效中具有独特的优势。但由于TRG依赖术后病理,挖掘TRG预测指标以更精准地选择适当的患者施行新辅助化疗成为当前的一个重要课题。因此,从生物标志物、免疫、炎症指标、身体成分、影像学指标等方面了解胃癌新辅助化疗后TRG预测因素的相关研究进展和当前研究面临的挑战,有助于进一步的临床研究和实践。
The overall efficacy of neoadjuvant chemotherapy for locally advanced gastric cancer has been recognized.However,neoadjuvant chemotherapy is ineffective in a subset of patients due to tumor heterogeneity.The tumor regression grade(TRG)has unique advantages in assessing the efficacy of neoadjuvant chemotherapy for gastric cancer.Nonetheless,since TRG is dependent on postoperative pathology,it becomes a significant topic today to mine TRG predictors to more accurately select appropriate patients for neoadjuvant chemotherapy.Therefore,to understand the relevant research progress and current research challenges of TRG predictors after neoadjuvant chemotherapy for gastric cancer from the aspects of biomarkers,immunity,inflammatory indicators,body composition,imaging indicators,etc.,is conducive to further clinical research and practice.
作者
范珊琳
汪品秀
孔飞
周玉洁
袁文臻
Fan Shanlin;Wang Pinxiu;Kong Fei;Zhou Yujie;Yuan Wenzhen(First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Department of Oncology,First Hospital of Lanzhou University,Lanzhou 730000,China)
出处
《国际肿瘤学杂志》
CAS
2023年第2期112-116,共5页
Journal of International Oncology
关键词
胃肿瘤
新辅助化疗
肿瘤退缩分级
预测因素
Stomachneoplasms
Neoadjuvantchemotherapy
Tumorregressiongrade
Predictivefactors
